CD47 and neoplasm: Several ligands, antibodies, or short peptide-modified nanocarriers, including transferrin, folic acid, and anti-CD47 antibodies, with high specificity and affinities have been developed, considering the specific high expression of receptors or protein antigens on tumor cell membranes (Figure 5) (Muhamad et al., 2018).